Nektar’s rezpegaldesleukin meets endpoints in Phase 2b atopic dermatitis trial

Nektar (NKTR) announced statistically significant data from the 16-week induction period of the ongoing Phase 2b REZOLVE-AD study of investigational rezpegaldesleukin in 393 patients with moderate-to-severe atopic dermatitis. The trial met its primary endpoint of the mean improvement in Eczema Area and Severity Score from baseline at week 16 for all three dose arms vs. placebo. All three dose arms also achieved statistical significance at week 16 for the key secondary endpoints of EASI-75 – percent of patients who achieve greater than or equal to75% reduction in EASI from baseline -, EASI-50 and BSA – mean percent improvement in Body Surface Area score from baseline -. The q2w arms of rezpegaldesleukin achieved statistical significance at week 16 for the key secondary endpoints of vIGA-AD 0/1and Itch NRS. In addition, at week 16, the high dose of 24 microgram/kg q2w achieved statistical significance on EASI-90. Across all three dose arms, translational blood biomarker data demonstrate robust on-target and dose-dependent pharmacological activity. Nektar plans to submit these REZOLVE-AD 16-week induction results for presentation at a medical conference later in 2025. The safety profile for the 16-week induction period for rezpegaldesleukin was consistent with previously reported results. Top-line Phase 2b data for rezpegaldesleukin in alopecia areata expected in Q4 2025